BAF NEWS

Newell Brands to cut 900 jobs as part of a global productivity plan, impacting about 3.8% of its workforce and focusing on office and shared services roles. The restructuring, including Yankee Candle store closures, aims to stabilize margins and achieve annualized cost savings of $110–130 million, with limited effect on manufacturing or supply chain operations.

Nexperia urges China units November 2025 highlights the company's public appeal for its China entities to re-engage and restore supply chain flows after regulatory disruptions. The article details the timeline of halted shipments, governance disputes, and proposed structured negotiations aimed at stabilizing cross-border chip logistics and minimizing production risks for customers.

HP 6,000 job cuts 2028 highlights HP's plan to reduce its workforce by up to 6,000 roles by FY2028 as part of an AI-driven restructuring aimed at saving $1 billion. The article also covers major tech sector developments, including Amazon's $50B AWS investment, Meta's Google TPU deal, Dell's AI server guidance, and key consumer and security trends.

The Wegovy 7.2 mg FDA filing marks Novo Nordisk's bid to introduce a higher once-weekly dose for adults with obesity, aiming for faster review under the FDA's accelerated pilot program. The application builds on STEP UP trial data, showing greater average weight loss, and could lead to a decision within 1–2 months if accepted.

Best Buy raises FY26 guidance following a strong Q3 performance, with comparable sales up 2.7% and revenue surpassing expectations. The company attributes this outlook upgrade to steady consumer demand, category momentum in computing and gaming, and effective tariff management, setting a positive tone for the holiday quarter.

The amycretin phase 2 results 2025 show that Novo Nordisk’s dual GLP-1 and amylin agonist achieved up to 14.5% weight loss and significant HbA1c reductions in adults with type 2 diabetes over 36 weeks. Both weekly injection and daily oral regimens were well tolerated, supporting advancement to phase 3 trials in 2026.